Please be aware that this website relies on the use of cookies to function correctly and involves some cookies being downloaded onto your device. By continuing to use this website, you agree to our use of these cookies. This helps us to improve the content of the website so that it is more useful and relevant to you. For more information please see our Privacy Policy.

PACE

Patient Access to Cancer care Excellence


A Global Vision

Faster steps forward: towards cures for cancer and access to best treatment and care for individual patients.

Learn more about PACE

William (Bill) McGivney, Ph.D.

Bill McGivney is Principal at McGivney Global Advisors LLC, a consulting company established in 2012 to advise pharma/biotech companies, investment houses and informatics companies regarding the positioning and use of drugs, biologics and devices in the marketplace.

Dr. McGivney was Chief Executive Officer of the National Comprehensive Cancer Network (NCCN) from 1997 through the end of 2011. At the NCCN, Dr. McGivney was responsible for the development of strategies and programs aimed at improving the quality of cancer care available to patients in need. Such programs include the NCCN Clinical Practice Guidelines in Oncology, the NCCN Drugs and Biologics Compendium, the NCCN Oncology Outcomes Database, the NCCN Managed Care Collaborations, the NCCN Oncology Research Program (ORP), and the NCCN’s collaboration with the National Business Group on Health.

In his 15-year tenure, Dr. McGivney built the NCCN into the most influential organization in the United States regarding the availability of, access to, and appropriate utilization of drugs, biologics, devices, and procedures in cancer care. The NCCN Guidelines are the standard of care in the United States and are being used globally. The NCCN Drugs and Biologics Compendium is the basis for coverage policy for private payers and was officially recognized by the Medicare Program in 2008. NCCN Guidelines also are used extensively by payers to set coverage policy. Bill expanded the NCCN’s business platform to include informatics collaborations, operational/business best practices, outcomes database development, and clinical trial collaborations. At the NCCN, he brought about a twelve-fold increase in the organization’s annual revenue. Prior to joining NCCN, Dr. McGivney worked at Aetna Health Plans between 1991 and 1997 as Vice President for Clinical and Coverage Policy. At Aetna, he directed several groups including national coverage policy, technology assessment, clinical guidelines, pharmacy policy and the Institutes of Excellence Network. In 1991, in collaboration with Grace Powers Monaco, he established the first formal independent outside review process. Dr. McGivney worked at the AMA from 1982 to 1991 where he was the Director of the Division of Health Care Technology and the AMA liaison to the FDA.

Dr. McGivney, a recognized expert in coverage policy and in drug and device regulatory policy, was awarded the FDA Commissioner's Medal of Appreciation. He has served on numerous national boards and committees including the Medicare Coverage Advisory Committee, as President of the Board of the Patient Advocate Foundation and National Patient Advocate Foundation and as member of the UNOS Board of Directors. He earned his bachelor’s and master’s degrees from Boston College, his Ph.D. from the University of North Carolina at Chapel Hill, and completed a postdoctoral fellowship at Harvard Medical School.